The page is the record's research on the issuer — no analyst, no rating, no view. # Gain Therapeutics, Inc. (NASDAQ: GANX) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Gain Therapeutics, Inc., listed on NASDAQ under ticker GANX, with ISIN US36269B1052. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-DE. The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted. ## The disclosure read The record holds 34 filings in the twelve months to 2026-11-08, across 19 filing days. The filings are 10 directors' dealings, 8 corporate news, 8 results, 3 AGM/EGM, 2 director changes, 2 regulatory filings and 1 prospectus. The median gap between filing days is 15.5 days. The latest filing is dated 2026-10-30, a directors' dealings filing, 9 days before the record date. The exchange median is 52 filings, a cadence gap of 6.0 days and a latency of 5.0 days across 4359 issuers. The sector median is 63.0 filings, a cadence gap of 6.0 days and a latency of 4.0 days across 526 issuers. ## Auditor The auditor of record is Ernst & Young AG, located in Lugano, Switzerland. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations page. ## Open research No openly published research notes were found on the record. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's years sealed are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001819411.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/GANX (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1819411/000110465926035188/ganx-20251231x10k.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/GANX (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/GANX · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp